ESC Premium Access

Use of direct thrombin inhibitor on the day of atrial fibrillation ablation decreases incidence of silent cerebral ischemia detected by magnetic resonance imaging

Congress Presentation

About the speaker

Associate Professor Masahide Harada

Fujita Health University Hospital, Toyoake (Japan)
0 follower

9 more presentations in this session

Prevalence and risk of DOACs inappropriate dosing in atrial fibrillation. An analysis of the Swiss-AF and BEAT-AF registries

Speaker: Doctor G. Montrasio (London, GB)


Heparin and low-molecular-weight heparin switch associated with an increase in bleeding complications in patients on apixaban undergoing catheter ablation: The AMPER ABLATION study

Speaker: Doctor W. Amara (Le Raincy-Montfermeil, FR)


Amiodarone treatment duration and reasons for permanent drug discontinuation in patients with atrial fibrillation

Speaker: Doctor M. Mihajlovic (Belgrade, RS)


Comparison of efficacy of different anticoagulation strategies used during pulmonary vein isolation in left atrial blood samples

Speaker: Doctor O. Hajas (Debrecen, HU)


Efficacy and safety of dronedarone after recent cardioversion in patients with atrial fibrillation/flutter: a post-hoc analysis of the EURIDIS/ADONIS trials

Speaker: Professor H. Crijns (Maastricht, NL)


Access the full session

Poster Session 2 - Drug treatment for atrial fibrillation

Speakers: Associate Professor M. Harada, Doctor G. Montrasio, Doctor W. Amara, Doctor M. Mihajlovic, Doctor O. Hajas...

About the event


ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb